[portable] — Ekdv-691

| Interim (Week 24) Result* | 30 mg | 60 mg | Placebo | |---------------------------|-------|-------|---------| | ΔFVC (mL) | | +78 ± 11 | – 38 ± 15 | | %ΔFVC (relative) | +5.8 % | +10.2 % | – 4.3 % | | PRO‑C3 ↓ (relative) | 31 % | 48 % | 3 % | | 6MWD ↑ (m) | +12 ± 4 | +21 ± 5 | – 5 ± 6 | | TEAEs (≥ 5 %) | GI upset (9 %), mild ALT ↑ (4 %) | GI upset (12 %), mild ALT ↑ (7 %) | Headache (7 %), nasopharyngitis (6 %) | | SAEs | 0 | 1 (transient hepatic transaminase rise) | 2 (exacerbation of IPF) |

The closer Alex got to the truth, the more they realized that EKDV-691 was not just a project but a new frontier in espionage. It had the potential to give its controllers unparalleled access to global communications and data. EKDV-691

In a 380‑kinase panel (DiscoverX KINOMEscan), EKDV‑691 shows > 95 % inhibition of ALK5 (IC₅₀ ≈ 4 nM) and DDR1 (IC₅₀ ≈ 12 nM) while sparing > 300 other kinases at 1 µM, including VEGFR2, PDGFRβ, and the cardiac hERG channel (IC₅₀ > 30 µM). | Interim (Week 24) Result* | 30 mg